Skip to main content

Table 1 Inputs and assumptions for outpatient pneumococcal pneumonia for sample pediatric and adult age groups: 0- < 5 and 50- < 65 years*

From: Attributable healthcare utilization and cost of pneumoniae due to drug-resistant Streptococcus pneumoniae: a cost analysis

    

Outcomes (% Cases)

    

Concordant treatment

Discordant treatment

Sample age groups

Antibiotic

% cases receiving antibiotic

% cases treated discordantly

% simple cure

% delayed cure

% delayed cure and hospitalized

% simple cure

% delayed cure

% delayed cure and hospitalized

Pediatric (0- < 5 yrs)

Amoxicillin (High dose)

9%

37%

71%

24%

5%

69%

23%

8%

Amoxicillin (Low dose)

7%

37%

71%

24%

5%

68%

23%

9%

Augmentin

11%

37%

71%

24%

5%

69%

23%

8%

Azithromycin

28%

32%

71%

24%

5%

45%

15%

40%

Oral Cephalosporin (2nd generation)

7%

8%

71%

24%

5%

68%

22%

10%

Oral Cephalosporin (3rd generation)

24%

8%

71%

24%

5%

68%

22%

10%

IM Ceftriaxone

14%

8%

71%

24%

5%

68%

23%

10%

Adult (50- < 65 yrs)

Amoxicillin

2%

37%

81%

14%

5%

77%

14%

9%

Augmentin

19%

37%

81%

14%

5%

77%

14%

9%

Azithromycin

15%

29%

81%

14%

5%

51%

9%

40%

Oral Cephalosporin (3rd generation)

9%

6%

81%

14%

5%

77%

14%

10%

IM Ceftriaxone

5%

6%

81%

14%

5%

77%

14%

10%

Fluoroquinolones

56%

1%

81%

14%

5%

51%

9%

40%

  1. *Derived from reference 11. Two age groups are shown as examples of model assumptions and inputs.